SpringWorks Therapeutics, Inc. (SWTX)
|52 Week Range||18.0-34.16|
|1y Target Est||-|
|DCF Unlevered||SWTX DCF ->|
|DCF Levered||SWTX LDCF ->|
|Debt / Equity||1.86%||Neutral|
Upgrades & Downgrades
Latest SWTX news
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
29 November 2023
The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.
SpringWorks Therapeutics Shares Skyrocket on FDA Approval of Desmoid Tumor Drug
28 November 2023
Shares of SpringWorks Therapeutics (SWTX) soared over 18% Tuesday after the Food and Drug Administration (FDA) gave its approval for the use of its pill to treat adults with non-cancerous growths in t...
SpringWorks Therapeutics' stock jumps after FDA approves first treatment for rare type of aggressive...
28 November 2023
SpringWorks Therapeutics Inc. shares SWTX jumped more than 9% premarket on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of non-cancerous but aggres...
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment
27 November 2023
The U.S. health regulator on Monday approved SpringWorks Therapeutics' drug for treating adult patients with desmoid tumors, making it the first approved treatment for this type of non-cancerous soft-...
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
17 November 2023
SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.
SpringWorks Therapeutics: How A Likely FDA Approval Can Kickstart The Stock's Repricing Potential
14 November 2023
SpringWorks Therapeutics' lead candidate, Nirogacestat, for treating Desmoid tumors, is coming up for an FDA decision - PDUFA date - on 27 November. I believe that an FDA approval for Nirogacestat in ...
SpringWorks Therapeutics: FDA Decision Date Ahead
12 July 2023
Today we revisit SpringWorks Therapeutics, Inc. for the first time in nearly a year. The company's primary drug asset is on the cusp of garnering SpringWorks' first FDA approval for a rare affliction....
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conferenc...
7 June 2023
STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
5 June 2023
The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc's tumor treatment by three months as the health regulator needs more time to review additional da...